4.50
0.04 (1.01%)
| Penutupan Terdahulu | 4.45 |
| Buka | 4.45 |
| Jumlah Dagangan | 503,901 |
| Purata Dagangan (3B) | 1,749,638 |
| Modal Pasaran | 719,325,824 |
| Harga / Jualan (P/S) | 1.93 |
| Harga / Buku (P/B) | 2.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | -0.65% |
| Margin Operasi (TTM) | 28.01% |
| EPS Cair (TTM) | -0.010 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -19.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -76.20% |
| Nisbah Semasa (MRQ) | 3.62 |
| Aliran Tunai Operasi (OCF TTM) | 124.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 79.68 M |
| Pulangan Atas Aset (ROA TTM) | 13.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Ironwood Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.68% |
| % Dimiliki oleh Institusi | 105.29% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2024 | Pengumuman | Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 13 Nov 2024 | Pengumuman | Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference |
| 07 Nov 2024 | Pengumuman | Ironwood Pharmaceuticals Reports Third Quarter 2024 Results |
| 28 Oct 2024 | Pengumuman | Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 |
| 24 Oct 2024 | Pengumuman | Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |